Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice

Detection of amyloid plaques in the brain by in vivo neuroimaging is a very promising biomarker approach for early diagnosis of Alzheimer's disease (AD) and evaluation of therapeutic efficacy. Here we describe a new method to detect amyloid plaques by in vivo magnetic resonance imaging (MRI) based on the intracerebroventricular injection of a nontargeted gadolinium (Gd)-based contrast agent, which rapidly diffuses throughout the brain and increases the signal and contrast of magnetic resonance (MR) images by shortening the T1 relaxation time. This gain in image sensitivity after in vitro and in vivo Gd staining significantly improves the detection and resolution of individual amyloid plaques in the cortex and hippocampus of AD transgenic mice. The improved image resolution is sensitive enough to demonstrate an age-dependent increase of amyloid plaque load and a good correlation between the amyloid load measured by μMRI and histology. These results provide the first demonstration that nontargeted Gd staining can enhance the detection of amyloid plaques to follow the progression of AD and to evaluate the activity of amyloid-lowering therapeutic strategies in longitudinal studies.

[1]  Marc Dhenain,et al.  In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice , 2006, Neurobiology of Aging.

[2]  M. Dhenain,et al.  Passive staining: A novel ex vivo MRI protocol to detect amyloid deposits in mouse models of Alzheimer's disease , 2006, Magnetic resonance in medicine.

[3]  Markus Rudin,et al.  In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe , 2005, Nature Biotechnology.

[4]  K. Hynynen,et al.  Ultrasound Enhanced Delivery of Molecular Imaging and Therapeutic Agents in Alzheimer's Disease Mouse Models , 2008, PloS one.

[5]  G. Johnson,et al.  Contrast‐enhanced in vivo magnetic resonance microscopy of the mouse brain enabled by noninvasive opening of the blood‐brain barrier with ultrasound , 2010, Magnetic resonance in medicine.

[6]  Thomas Wisniewski,et al.  Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging , 2002, Neurobiology of Disease.

[7]  Thomas Wisniewski,et al.  Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging , 2003, Magnetic resonance in medicine.

[8]  H. Hirschberg,et al.  Site‐specific opening of the blood‐brain barrier , 2010, Journal of biophotonics.

[9]  Marc Dhenain,et al.  Senile plaques do not induce susceptibility effects in T 2*‐weighted MR microscopic images , 2002, NMR in biomedicine.

[10]  Agneta Nordberg,et al.  Amyloid imaging in Alzheimer's disease , 2008, Neuropsychologia.

[11]  S. DeKosky,et al.  Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.

[12]  M. Dhenain,et al.  Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice , 2007, Magnetic resonance in medicine.

[13]  Clifford R Jack,et al.  In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice , 2005, The Journal of Neuroscience.

[14]  G Allan Johnson,et al.  Staining methods for magnetic resonance microscopy of the rat fetus , 2007, Journal of magnetic resonance imaging : JMRI.

[15]  Arthur W. Toga,et al.  Purkinje cell loss in experimental autoimmune encephalomyelitis , 2009, NeuroImage.

[16]  Michael Garwood,et al.  In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent , 2004, Magnetic resonance in medicine.

[17]  Qing X Yang,et al.  MRI and histological analysis of beta‐amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice , 2009, Journal of magnetic resonance imaging : JMRI.

[18]  M. Dhenain Preclinical MRI and NMR Biomarkers of Alzheimer’s Disease: Concepts and Applications , 2008 .

[19]  L. Hedlund,et al.  Morphologic phenotyping with MR microscopy: the visible mouse. , 2002, Radiology.

[20]  A. Sbarbati,et al.  In Vitro and In Vivo Study of Solid Lipid Nanoparticles Loaded with Superparamagnetic Iron Oxide , 2003, Journal of drug targeting.

[21]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[22]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[23]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[24]  F. LaFerla,et al.  Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease , 2009, Neuropharmacology.

[25]  Marc Dhenain,et al.  Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease , 2006, Neurobiology of Disease.

[26]  Ryan Chamberlain,et al.  Comparison of amyloid plaque contrast generated by T2‐weighted, T  2* ‐weighted, and susceptibility‐weighted imaging methods in transgenic mouse models of Alzheimer's disease , 2009, Magnetic resonance in medicine.

[27]  T Deffieux,et al.  Numerical study of a simple transcranial focused ultrasound system applied to blood-brain barrier opening , 2010, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[28]  Ferenc A. Jolesz,et al.  Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications , 2005, NeuroImage.

[29]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[30]  C. Fallet-Bianco,et al.  Magnetic resonance imaging and histological studies of corpus callosal and hippocampal abnormalities linked to doublecortin deficiency , 2007, The Journal of comparative neurology.

[31]  Thomas Wisniewski,et al.  A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice , 2008, Neurobiology of Aging.

[32]  G. Allan Johnson,et al.  Neuroanatomical phenotypes in the Reeler mouse , 2007, NeuroImage.

[33]  Marc Dhenain,et al.  Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice , 2009, Neurobiology of Aging.

[34]  G. Johnson,et al.  Magnetic Resonance Microscopy of the C57BL Mouse Brain , 2000, NeuroImage.

[35]  T. Bayer,et al.  Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice , 2003, Experimental Neurology.

[36]  G. Hoffman,et al.  cFos immunoreactivity is enhanced with biotin amplification. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[37]  Nobuhisa Iwata,et al.  19F and 1H MRI detection of amyloid beta plaques in vivo. , 2005, Nature neuroscience.

[38]  A. Petiet,et al.  In Vivo Imaging Biomarkers in Mouse Models of Alzheimer's Disease: Are We Lost in Translation or Breaking Through? , 2010, International journal of Alzheimer's disease.

[39]  D. Dickstein,et al.  Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model , 2003 .

[40]  M. Essig,et al.  High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review , 2010, European Radiology.